• Users Online:1775
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 10  |  Issue : 1  |  Page : 6-23

A multicentric, double-blind randomized, homoeopathic pathogenetic trial of Allium sativum


1 Central Council for Research in Homoeopathy, New Delhi, India
2 Homoeopathic Treatment Center, Safdarjung Hospital, New Delhi, India
3 Nodal Office and Center for Drug Proving Research Study, Dr. D. P. Rastogi Central Research Institute (H), Noida, Uttar Pradesh, India
4 Center for Drug Proving Study, Central Research Institute (H), Kottayam, Kerala, India

Correspondence Address:
Pritha Mehra
Dr. D. P. Rastogi Central Research Institute (H), A 1/1, Sector 24, Noida, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-7168.179152

Rights and Permissions

Background: Homoeopathic drug proving is an integral part of Homoeopathic System of Medicine. It is the first step in finding out the pathogenetic powers of a drug. Objective: To elicit the pathogenetic response to Allium sativum in homoeopathic potencies on healthy human provers. Materials and Methods: A multi-center randomized, placebo-controlled, double-blind trial was conducted at two centers of the Central Council for Research in Homoeopathy (CCRH). Proving was conducted on 33 healthy provers after the pretrial medical examination. All the provers were given 12 doses of placebo divided in 4 doses/day for 3 days during the first phase of the trial. After randomization, in the intervention group (21 provers), Allium sativum (A. sativum) was proved in 6C and 30C potencies, in two phases. In the placebo group, 12 provers were administered placebo in the same manner. The symptoms manifested during the trial period were noted down by the provers and then elaborated by the proving masters. The generated data on A. sativum were then compiled and analyzed at proving-cum-data processing cell at CCRH headquarters. Results: Out of 21 provers who were on actual drug trial, only nine provers manifested symptoms. Drug was able to manifest symptoms in both the potencies, in more or less every part of the body. Conclusion: The pathogenetic response elicited during the proving trial expands the scope of use of the drug A. sativum and will benefit the research scholars and clinicians. The generated symptoms of this drug will carry more value when verified clinically.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2920    
    Printed25    
    Emailed0    
    PDF Downloaded557    
    Comments [Add]    

Recommend this journal